Trial Profile
Pirfenidone and nintedanib in patients with Idiopathic pulmonary fibrosis (IPF)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Nov 2017
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Pirfenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- 16 Nov 2017 New trial record